Stephan A. Schug
Emeritus Professor, MD Cologne, FANZCA, FFPMANZCA, EDPM
Senior Honorary Research Fellow, Faculty of Health and Medical Sciences,
University of Western Australia Medical School
Dr. Schug is currently an Honorary Senior Research Fellow and Emeritus Professor. Until his retirement, he served as Professor and Chair of Anaesthesiology and Pain Medicine in the Medical School of the University of Western Australia and Director of Pain Medicine at the Royal Perth Hospital, Australia. He has written over 85 research and 180 review papers, as well as abstracts, letters, and editorials, and has edited or co-authored several books, book chapters, and monographs. He is currently on editorial and review boards of several leading journals including Pain & Therapy, Annals of Palliative Medicine, Current Opinion in Anaesthesiology, Best Practice in Anesthesiology Research, Canadian Journal of Pain, and CNS Drugs. Professor Schug is an active member of several pain and anaesthesia societies including Chair of the SIG Acute Pain of IASP and Chair of the SIG Acute Pain of ACE (ANZCA, ASA, NZSA), Secretary General of Asian & Oceanic Society of Regional Anaesthesia (AOSRA )and is a Fellow of the Australian and New Zealand College of Anaesthetists (ANZCA) and its Faculty of Pain Medicine (FPMANZCA), where he is a member of the Board of the Faculty. Dr. Schug received his MD from the University of Cologne, Germany.
President at Revati Inc.
Dr. Shreeniwas brings over 20 years of drug development expertise to Xgene. Her background includes experience in several therapeutic areas including pain, inflammation, neurology. She has held roles of increasing responsibility in several companies including CV Therapeutics, Actelion Pharmaceuticals, and Alvine Pharmaceuticals where she supervised the development of novel compounds. Her drug development consulting practice provides strategic development expertise to the pharmaceutical industry. She is licensed to practice medicine in California and has served on the faculty of Stanford University and The College of Physicians and Surgeons at Columbia University.
Peter George Lacouture
Ph.D., Vice President of Scientific and Medical Affairs, Magidom Discovery, Adjunct Assistant Professor of Medine, Brown University School of Medicine
Peter G. Lacouture is co-founder and Vice President, Scientific & Medical Affairs for Magidom Discovery (MD), an international boutique strategic and tactical operations firm focused on regulatory and clinical aspects of pain management/analgesic discovery and development. Dr. Lacouture has deep industry, academic, and regulatory expertise in pain medicine with experience ranging from development and manufacturing to marketing. He previously served as Medical Director of Pain Management at Hospira, Inc. and Clinical/Medical lead at Purdue Pharma and Wyeth-Ayerst Research (now Pfizer). Dr. Lacouture’s experience includes all phases of development, multiple routes of administration, and acute and chronic pain in nociceptive, neuropathic and inflammatory pathologies. He has held faculty positions at Harvard University (Pediatrics) and the University of Pennsylvania (Anesthesia), and is currently Adjunct Assistant Professor of Medicine at Brown University (Emergency Medicine). He was one of the founders of the Pediatric Pain Service at Children’s Hospital in Boston. He has authored almost two hundred publications. Lacouture received his Ph.D. in Pharmacology/Physiology from the Massachusetts College of Pharmacy and Health Sciences and completed his post-doctoral training in Pathology at Harvard University Medical School.
Allen G. Downs
Principal at Reach Consulting, LLC
Allen Downs is a principal at Reach Consulting, LLC specializing in life sciences business development. His career has spanned three decades with pharmaceutical licensing, business development, alliance management, and product development roles at Mundipharma in the UK, Purdue Pharma in the US, and Bristol-Myers Squibb in the US and Japan. Mr. Downs is a graduate of the University of Pennsylvania (MS, Chemical Engineering) with a thesis in bioengineering, and the Harvard Business School (MBA).